Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00907062 |
Recruitment Status :
Completed
First Posted : May 22, 2009
Last Update Posted : July 8, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Vitiligo Vulgaris | Dietary Supplement: Ginkgo biloba | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents: an Open Label Pilot Clinical Trial |
Study Start Date : | May 2009 |
Actual Primary Completion Date : | October 2009 |
Actual Study Completion Date : | November 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: Gingko biloba
60 mg of Ginkgo biloba (standardized to 15 mg ginkgofavonglycosides) given 2 times per day, with food, for 12 weeks.
|
Dietary Supplement: Ginkgo biloba
60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill |
- Vitiligo European Task Force assessment form [ Time Frame: 12 weeks ]
- Vitiligo Area Scoring Index [ Time Frame: 12 weeks ]
- Health Canada - Canada Vigilence Adverse Reaction Form [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
-
• males and females
- 12 to 18 years old
- self selected candidates identifying themselves to suffer with vitiligo vulgaris of any duration
- minimum VASI score of 4, no maximum score (corresponding to a 3cm2 completely (100%) depigmented lesion, or a 6cm2 50% depigmented lesion)
- stable or progressing vitiligo
- mentally competent subjects able to adhere to the given protocol and treatments administered as interventions
- normal on physical examination at the pre-study intake, and in the case of abnormalities the health care practitioner considers them to be clinically insignificant
- written and informed consent
- the potential candidate must have a family doctor that they have seen in the last 12 months
- negative pregnancy test for menstruating women and if sexually active, a willingness to practice adequate birth control for the duration of the trial
- diagnosis of vitiligo confirmed by supervising medical doctor
Exclusion Criteria:
-
• use of medications contraindicated with Ginkgo biloba:
- daily use of acetylsalicylic acid, ibuprofen, NSAIDs, fish oils, vitamin E
- any prescription or use of blood thinners, anticoagulants, anti-platelet drugs, pentoxifylline, clotting factor replacements, antihypertensive medications, Thiazide diuretics, Acetylcholinesterase inhibitors, anticonvulsants, hypoglycemic agents, MAOI, SSRI, Nifedipine, Papaverine, Yohimgine, Sildenafil
- history of diabetes, seizures, haemophilia
- allergy or sensitivity to Ginkgo biloba or other constituents in the capsule
- any treatment for vitiligo within the last 2 months
- current use of Ginkgo biloba or within the last 2 months
- mentally or physically incapacitated such that assent or informed consent cannot be obtained.
- any history or other condition which the study physician regards as clinically significant to the study
- a major illness considered to be clinically significant by the study physician within 2 months of the study start date
- current participation in another intervention trial.
- pregnancy or intent to become pregnant in the next 4 months
- current alcoholism or substance abuse.
- current history of tumors, any history of skin cancer
- any current serious disorders determined to be clinically significant to the study.
- breast feeding women
- no prior skin grafts or surgeries, or scheduled surgeries of any kind.
- any abnormalities on the INR, PTT, or CBC tests at baseline

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00907062
Canada, Ontario | |
Noumena Naturopathic Health Clinic | |
Mississauga, Ontario, Canada, L5H 1H2 |
Principal Investigator: | Orest Szczurko, ND MSc(cand) | University of Toronto, Leslie Dan Faculty of Pharmacy | |
Principal Investigator: | Heather Boon, PhD | University of Toronto, Leslie Dan Faculty of Pharmacy |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Heather Boon, Associate Professor, Leslie Dan Faculty of Pharmacy, University of Toronto |
ClinicalTrials.gov Identifier: | NCT00907062 |
Other Study ID Numbers: |
NHPD#-137767 REB 23373 |
First Posted: | May 22, 2009 Key Record Dates |
Last Update Posted: | July 8, 2010 |
Last Verified: | July 2010 |
vitiligo leucoderma |
Vitiligo Hypopigmentation Pigmentation Disorders Skin Diseases |